On this video, Marc Bjurlin, DO, MSc, FACOS, discusses efforts to scale back smoking in sufferers with bladder most cancers. He’s an creator of the AUA 2024 summary “Efficacy of inpatient, evidence-based tobacco use remedy of sufferers with bladder most cancers after radical cystectomy.” Bjurlin is director of medical trials and an affiliate professor of urology on the College of North Carolina, Chapel Hill.
Transcription:
Does your group plan to discover additional measures to scale back smoking in sufferers with bladder most cancers? If that’s the case, what’s going to these measures entail?
We now have a few concepts that we’re engaged on now. First, we need to ensure that this type of inpatient put up cystectomy smoking program is sustainable. So we’re persevering with this ahead for quite a lot of years, so we are able to truly look, was this type of a 1-time venture that we received these nice numbers? Or can we truly proceed this as a part of our regular pathway in sufferers who smoke and bear cystectomy? After which we’re additionally transitioning a little bit bit, in that we studied the supplier’s function in offering smoking cessation. We checked out our tobacco remedy program and the way they supply smoking cessation. However what we’ve not completed but is absolutely appeared on the affected person expertise, which means, what are the limitations and what are the facilitators that our sufferers have skilled with a purpose to stop smoking? So our subsequent objective is transitioning to essentially perceive the affected person expertise and the way we are able to assist them to stop smoking cigarettes.
This transcription was edited for readability.
